

Part VI: Summary of the risk management plan**Summary of risk management plan for Fesoterodine Accord 8 mg Prolonged-Release Tablets (Fesoterodine Fumarate)**

This is a summary of the risk management plan (RMP) for Fesoterodine Accord 8 mg Prolonged-Release Tablets. The RMP details important risks of Fesoterodine Accord 8 mg Prolonged-Release Tablets, how these risks can be minimised, and how more information will be obtained about Fesoterodine Accord 8 mg Prolonged-Release Tablets's risks and uncertainties (missing information).

Fesoterodine Accord 8 mg Prolonged-Release Tablets's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Fesoterodine Accord 8 mg Prolonged-Release Tablets should be used.

Important new concerns or changes to the current ones will be included in updates of Fesoterodine Accord 8 mg Prolonged-Release Tablets's RMP.

I. The medicine and what it is used for

Fesoterodine Accord 8 mg Prolonged-Release Tablets is indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.

It contains fesoterodine fumarate as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Fesoterodine Accord 8 mg Prolonged-Release Tablets together with measures to minimise such risks and the proposed studies for learning more about Fesoterodine Accord 8 mg Prolonged-Release Tablets' risks, are outlined below.

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorization Holder.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of 'Fesoterodine Accord 8 mg Prolonged-Release Tablets' is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Fesoterodine Accord 8 mg Prolonged-Release Tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Fesoterodine Accord 8 mg Prolonged-Release Tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Important identified risks	<ul style="list-style-type: none"> • Urinary retention • Angioedema
Important potential risks	<ul style="list-style-type: none"> • QT prolongation

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorization Holder.

	<ul style="list-style-type: none"> • Liver enzyme elevations • Cognitive function impairment
Missing information	<ul style="list-style-type: none"> • Elderly male patients • Paediatric patients • Pregnant or nursing women

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Fesoterodine Accord 8 mg prolonged-release tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Fesoterodine Accord 8 mg Prolonged-Release Tablets.